A potential target can also be represented by Akt, tested only in CLL with the allosteric inhibitor MK-2206, in combination with a BR (rituximab plus bendamustine) regimen (Figure 2) [121]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.